Vizza, Carmine Dario ORCID: 0000-0002-3540-4983, Hoeper, Marius M., Huscher, Doerte, Pittrow, David, Benjamin, Nicola, Olsson, Karen M., Ghofrani, H. Ardeschir, Held, Matthias, Klose, Hans, Lange, Tobias, Rosenkranz, Stephan, Dumitrescu, Daniel, Badagliacca, Roberto, Claussen, Martin, Halank, Michael, Vonk-Noordegraaf, Anton, Skowasch, Dirk, Ewert, Ralf, Gibbs, J. Simon R., Delcroix, Marion ORCID: 0000-0001-8394-9809, Skride, Andris ORCID: 0000-0002-1087-687X, Coghlan, Gerry, Ulrich, Silvia, Opitz, Christian, Kaemmerer, Harald, Distler, Oliver and Grunig, Ekkehard (2021). Pulmonary Hypertension in Patients With COPD Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Chest, 160 (2). S. 678 - 690. AMSTERDAM: ELSEVIER. ISSN 1931-3543

Full text not available from this repository.

Abstract

BACKGROUND: Pulmonary hypertension (PH) in COPD is a poorly investigated clinical condition. RESEARCH QUESTION: Which factors determine the outcome of PH in COPD? STUDY DESIGN AND METHODS: We analyzed the characteristics and outcome of patients enrolled in the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) with moderate or severe PH in COPD as defined during the 6th PH World Symposium who received medical therapy for PH and compared them with patients with idiopathic pulmonary arterial hypertension (IPAH). RESULTS: The population included incident patients with moderate PH in COPD (n = 68), with severe PH in COPD (n = 307), and with IPAH (n = 489). Patients with PH in COPD were older, predominantly male, and treated mainly with phosphodiesterase-5 inhibitors. Despite similar hemodynamic impairment, patients with PH in COPD achieved a worse 6-min walking distance (6MWD) and showed a more advanced World Health Organization functional class (WHO FC). Transplant-free survival rates at 1, 3, and 5 years were higher in the IPAH group than in the PH in COPD group (IPAH: 94%, 75%, and 55% vs PH in COPD: 86%, 55%, and 38%; P = .004). Risk factors for poor outcomes in PH in COPD were male sex, low 6MWD, and high pulmonary vascular resistance (PVR). In patients with severe PH in COPD, improvements in 6MWD by >= 30 m or improvements in WHO FC after initiation of medical therapy were associated with better outcomes. INTERPRETATION: Patients with PH in COPD were functionally more impaired and had a poorer outcome than patients with IPAH. Predictors of death in the PH in COPD group were sex, 6MWD, and PVR. Our data raise the hypothesis that some patients with severe PH in COPD may benefit from PH treatment. Randomized controlled studies are necessary to explore this hypothesis further.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Vizza, Carmine DarioUNSPECIFIEDorcid.org/0000-0002-3540-4983UNSPECIFIED
Hoeper, Marius M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Huscher, DoerteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pittrow, DavidUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Benjamin, NicolaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Olsson, Karen M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ghofrani, H. ArdeschirUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Held, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klose, HansUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lange, TobiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosenkranz, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dumitrescu, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Badagliacca, RobertoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Claussen, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Halank, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Vonk-Noordegraaf, AntonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Skowasch, DirkUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ewert, RalfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gibbs, J. Simon R.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Delcroix, MarionUNSPECIFIEDorcid.org/0000-0001-8394-9809UNSPECIFIED
Skride, AndrisUNSPECIFIEDorcid.org/0000-0002-1087-687XUNSPECIFIED
Coghlan, GerryUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ulrich, SilviaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Opitz, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaemmerer, HaraldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Distler, OliverUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grunig, EkkehardUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-606670
DOI: 10.1016/j.chest.2021.02.012
Journal or Publication Title: Chest
Volume: 160
Number: 2
Page Range: S. 678 - 690
Date: 2021
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 1931-3543
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
SILDENAFIL; DISEASE; SURVIVAL; OUTCOMES; VOLUMEMultiple languages
Critical Care Medicine; Respiratory SystemMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60667

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item